CN110272419A - 二氢吡啶并酞嗪酮衍生物、其制备方法及应用 - Google Patents

二氢吡啶并酞嗪酮衍生物、其制备方法及应用 Download PDF

Info

Publication number
CN110272419A
CN110272419A CN201810216030.4A CN201810216030A CN110272419A CN 110272419 A CN110272419 A CN 110272419A CN 201810216030 A CN201810216030 A CN 201810216030A CN 110272419 A CN110272419 A CN 110272419A
Authority
CN
China
Prior art keywords
base
dihydro
fluoro
fluorophenyl
phthalazines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810216030.4A
Other languages
English (en)
Chinese (zh)
Inventor
罗会兵
周华勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Allist Pharmaceuticals Inc
Original Assignee
Shanghai Allist Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Allist Pharmaceuticals Inc filed Critical Shanghai Allist Pharmaceuticals Inc
Priority to CN201810216030.4A priority Critical patent/CN110272419A/zh
Priority to PCT/CN2019/078089 priority patent/WO2019174607A1/fr
Priority to CN201980018770.XA priority patent/CN111868060B/zh
Publication of CN110272419A publication Critical patent/CN110272419A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201810216030.4A 2018-03-14 2018-03-14 二氢吡啶并酞嗪酮衍生物、其制备方法及应用 Pending CN110272419A (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201810216030.4A CN110272419A (zh) 2018-03-14 2018-03-14 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
PCT/CN2019/078089 WO2019174607A1 (fr) 2018-03-14 2019-03-14 Dérivé de dihydropyridophtalazinone, son procédé de préparation et son utilisation
CN201980018770.XA CN111868060B (zh) 2018-03-14 2019-03-14 二氢吡啶并酞嗪酮衍生物、其制备方法及应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810216030.4A CN110272419A (zh) 2018-03-14 2018-03-14 二氢吡啶并酞嗪酮衍生物、其制备方法及应用

Publications (1)

Publication Number Publication Date
CN110272419A true CN110272419A (zh) 2019-09-24

Family

ID=67908581

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810216030.4A Pending CN110272419A (zh) 2018-03-14 2018-03-14 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
CN201980018770.XA Active CN111868060B (zh) 2018-03-14 2019-03-14 二氢吡啶并酞嗪酮衍生物、其制备方法及应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980018770.XA Active CN111868060B (zh) 2018-03-14 2019-03-14 二氢吡啶并酞嗪酮衍生物、其制备方法及应用

Country Status (2)

Country Link
CN (2) CN110272419A (fr)
WO (1) WO2019174607A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022222964A1 (fr) * 2021-04-23 2022-10-27 成都百裕制药股份有限公司 Dérivé de pyridine et son utilisation en médecine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA11749A (en) * 1999-01-11 2005-07-19 Agouron Pharma Tricyclic inhibitors of poly(adp-ribose)polymerases.
SG10201809895YA (en) * 2008-08-06 2018-12-28 Medivation Tech Llc Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
WO2013028495A1 (fr) * 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Inhibiteurs dihydropyridophthalazinone de poly (adp-ribose) polymérase (parp) pour le traitement du myélome multiple
US20130053365A1 (en) * 2011-08-30 2013-02-28 Biomarin Pharmaceutical, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)

Also Published As

Publication number Publication date
CN111868060B (zh) 2023-06-09
CN111868060A (zh) 2020-10-30
WO2019174607A1 (fr) 2019-09-19

Similar Documents

Publication Publication Date Title
CN102171214B (zh) 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
EP2945623B1 (fr) Inhibiteurs de la voie signalisation hedgehog et leurs applications thérapeutiques
CN104884458B (zh) 作为蛋白质激酶抑制剂的稠合杂环化合物
CN107253963B (zh) 吡啶酮和氮杂吡啶酮化合物及使用方法
CN104781259B (zh) 抑制bet蛋白的5-芳基三唑并氮杂*
CN107474050B (zh) 6，7-二氢吡唑并[1，5-a]吡嗪-4(5H)-酮化合物
JP2021138737A (ja) プロテインキナーゼ阻害剤及びその調製方法と医薬用途
EP3681885B1 (fr) Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300
JP2004507442A (ja) 複素環式ジヒドロピリミジン化合物
CN108884097B (zh) 嘧啶类衍生物、其制备方法和其在医药上的用途
HUE029275T2 (en) Phthalazinone ketone derivative, method of preparation and therapeutic use
CN102952118B (zh) 聚（adp-核糖）聚合酶抑制剂、制备方法及其用途
CN110914277B (zh) 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
CN114423753A (zh) 作为cd38抑制剂的杂双环酰胺
CN107531714A (zh) 作为pde1抑制剂的咪唑并吡嗪酮
CN111499634A (zh) 一种喹唑啉化合物及其在医药上的应用
CN117980307A (zh) 取代的三环类化合物作为parp抑制剂及其应用
CN110167941A (zh) 取代的稠合杂芳基化合物作为激酶抑制剂及其应用
WO2023025116A1 (fr) Dérivé hétérocyclique, son procédé de préparation et son utilisation en médecine
CN103228660A (zh) Kat ii 抑制剂
TW201900642A (zh) 作為ＬＲＲＫ２抑制劑之新穎咪唑並［４，５－ｃ］喹啉衍生物
TW202110848A (zh) 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用
CN110272419A (zh) 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
US20090143380A1 (en) 2h- or 3h-benzo[e]indazol-1-yl carbamate derivatives, the preparation and therapeutic use thereof
KR101854117B1 (ko) 1,6-이치환된 인돌 화합물을 함유하는 약물 내성 및 부작용이 저감된 만성골수성백혈병 치료제

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 201203 floor 5, building 1, No. 1118, Halley Road, No. 1227, zhangheng Road, Shanghai pilot Free Trade Zone

Applicant after: Shanghai ALLIST medicine Polytron Technologies Inc.

Address before: 201203, 5 floor, 1118 Harley Road, Zhangjiang hi tech park, Shanghai, Pudong New Area

Applicant before: Shanghai ALLIST medicine Polytron Technologies Inc.

Address after: 201203, 5 floor, 1118 Harley Road, Zhangjiang hi tech park, Shanghai, Pudong New Area

Applicant after: Shanghai ALLIST medicine Polytron Technologies Inc.

Address before: 201203, 5 floor, 1118 Harley Road, Zhangjiang hi tech park, Shanghai, Pudong New Area

Applicant before: SHANGHAI ALLIST PHARMACEUTICALS, Inc.

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190924